New brain drug ITI-333 tested in healthy volunteers for first time

NCT ID NCT05470101

Completed Knowledge-focused Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage study tested a single dose of the experimental drug ITI-333 in 12 healthy adults. Researchers used brain scans to see how much of the drug attached to a specific receptor (5-HT2A) in the brain. They also checked safety, side effects, and how the drug moves through the body. The goal was to gather basic information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ITI-333
What this could lead to: If successful, this study could help determine the right dose for future trials of ITI-333 in conditions like psychiatric disorders.
What could go wrong: This is a very early, small study in only 12 healthy people. It is not designed to test if the drug works for any disease, and results may not predict effects in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Clinical Site 1

St Louis, Missouri, 63110, United States
Clinical Site 2

Creve Coeur, Missouri, 63141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.